Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 49.0% in December

Talphera, Inc. (NASDAQ:TLPH) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 30,500 shares, a drop of 49.0% from the December 15th total of 59,800 shares. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are sold short.

Talphera Price Performance

Shares of NASDAQ TLPH opened at $0.58 on Tuesday. The company’s 50 day simple moving average is $0.69 and its 200 day simple moving average is $0.83. Talphera has a fifty-two week low of $0.50 and a fifty-two week high of $1.61. The firm has a market capitalization of $9.81 million, a P/E ratio of -0.84 and a beta of 0.28.

Institutional Investors Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new position in shares of Talphera, Inc. (NASDAQ:TLPH) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for approximately 0.4% of Rosalind Advisors Inc.’s holdings, making the stock its 25th biggest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent reporting period. 37.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Maxim Group upgraded Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.